BioSpace News Archive

Olympus Corporation today announced that it has finalized the acquisition of Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, fol

Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 PM ET

Innovative, novel approach to treat and protect against SARS-CoV-2 using thermoresponsive virus-targeting nanoparticles as an inhalation medicine Program includes development of a heat-sensitive fluorescent SARS-CoV-2 detection assay through patient mucosal sampling

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced its corporate partners, Alphamab Oncology and 3D Medicines, received notification that the Chine

Assure Holdings Corp., a provider of intraoperative neuromonitoring services, is pleased to announce that upon paying US$3,171,540 on December 24, 2020, it has made the final payment in connection with the previously announced acquisition of all of the assets of Neuro-Pro Monitoring.

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhawan, providing a review of 2020.

Expands physician and patient access to Biocept’s Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer

BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of U.S. Patent No: 10,874, 831 for “Devices and Methods for Accessing the Vasculature of a Patient” that further protects the Helix™ Biotherapeutic Delivery System and enhances its cell therapy delivery capabilities. This patent covers a steerable design intended to provide

VistaGen Therapeutics , Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, announced today that Dr. Louis Monti, VistaGen Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member

ImmunityBio, Inc., a privately-held immunotherapy company, today announced that it has appointed Fabio M. Benedetti, M.D., as Chief Strategy Officer, effective January 4, 2021. Dr. Benedetti brings more than 20 years of biotech and large pharma experience in oncology clinical development and medical affa